Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by carduon Jan 23, 2011 4:41pm

446 Views

Post# 18014620

RE: RE: RE: Oncolytics featured in Reader's Digest

After reading the article it almost prompts you to buy up every share you can afford. This article combined with the Daily Mail (UK) article on Breezy Marsh in 2009 points to a possible blockbuster treatment that won't be denied.

Fox news reported the US government is starting a fund to encourage investment in drug development because the big pharmas are NOT investing the billions required to finance new drugs.

Can only be good for ONC!

Bullboard Posts

Rising miner increases graphite price, restarts Québec mill